Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP - TT).

Gates Open Research Pub Date : 2023-12-18 eCollection Date: 2023-01-01 DOI:10.12688/gatesopenres.14710.2
Rebecca Harding, Ernest Moya, Ricardo Ataíde, Zinenani Truwah, Glory Mzembe, Gomezgani Mhango, Ayşe V Demir, William Stones, Louise Randall, Marc Seal, Katherine Johnson, Stefan Bode, Martin N Mwangi, Sant-Rayn Pasricha, Sabine Braat, Kamija S Phiri
{"title":"Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP - TT).","authors":"Rebecca Harding, Ernest Moya, Ricardo Ataíde, Zinenani Truwah, Glory Mzembe, Gomezgani Mhango, Ayşe V Demir, William Stones, Louise Randall, Marc Seal, Katherine Johnson, Stefan Bode, Martin N Mwangi, Sant-Rayn Pasricha, Sabine Braat, Kamija S Phiri","doi":"10.12688/gatesopenres.14710.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anemia affects 40% of pregnant women globally, leading to maternal mortality, premature birth, low birth weight, and poor baby development. Iron deficiency causes over 40% of anemia cases in Africa. Oral iron supplementation is insufficient for Low-and-Middle-Income-Countries (LMICs) to meet current WHO targets. We hypothesized that a single intravenous dose of Ferric Carboxymaltose (FCM) may be more effective than oral iron treatment for anemia recovery, particularly in these settings where women present late for antenatal care.</p><p><strong>Methods: </strong>This is a two-arm parallel open-label individual-randomized controlled trial in third trimester, in malaria Rapid Diagnostic Test-negative pregnant women with moderate or severe anemia - capillary hemoglobin <10 g/dL - who are randomized to receive either parenteral iron - with FCM - or standard-of-care oral iron for the remainder of pregnancy. This is the sister trial to the second-trimester <b>REVAMP</b> trial, funded by the Bill and Melinda Gates Foundation (trial registration ACTRN12618001268235, Gates Grant number INV-010612). In REVAMP-TT, recruitment and treatment are performed within primary health centers. The trial will recruit 590 women across Zomba district, Malawi. The primary outcome is the proportion of anemic women - venous hemoglobin <11 g/dL - at 36 weeks' gestation or delivery (whichever occurs first). Other pre-specified key secondary clinical and safety outcomes include maternal iron-status and hypophosphatemia, neonate birth weight, infant growth and infant iron and hematological parameters.</p><p><strong>Discussion: </strong>This study will determine whether FCM, delivered within primary health centers, is effective, safe and feasible for treating moderate to severe anemia in third-trimester pregnant Malawian women. This intervention could have long-term benefits for maternal and child health, resulting in improved survival and child development.</p>","PeriodicalId":12593,"journal":{"name":"Gates Open Research","volume":"7 ","pages":"117"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10858019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gates Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/gatesopenres.14710.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Anemia affects 40% of pregnant women globally, leading to maternal mortality, premature birth, low birth weight, and poor baby development. Iron deficiency causes over 40% of anemia cases in Africa. Oral iron supplementation is insufficient for Low-and-Middle-Income-Countries (LMICs) to meet current WHO targets. We hypothesized that a single intravenous dose of Ferric Carboxymaltose (FCM) may be more effective than oral iron treatment for anemia recovery, particularly in these settings where women present late for antenatal care.

Methods: This is a two-arm parallel open-label individual-randomized controlled trial in third trimester, in malaria Rapid Diagnostic Test-negative pregnant women with moderate or severe anemia - capillary hemoglobin <10 g/dL - who are randomized to receive either parenteral iron - with FCM - or standard-of-care oral iron for the remainder of pregnancy. This is the sister trial to the second-trimester REVAMP trial, funded by the Bill and Melinda Gates Foundation (trial registration ACTRN12618001268235, Gates Grant number INV-010612). In REVAMP-TT, recruitment and treatment are performed within primary health centers. The trial will recruit 590 women across Zomba district, Malawi. The primary outcome is the proportion of anemic women - venous hemoglobin <11 g/dL - at 36 weeks' gestation or delivery (whichever occurs first). Other pre-specified key secondary clinical and safety outcomes include maternal iron-status and hypophosphatemia, neonate birth weight, infant growth and infant iron and hematological parameters.

Discussion: This study will determine whether FCM, delivered within primary health centers, is effective, safe and feasible for treating moderate to severe anemia in third-trimester pregnant Malawian women. This intervention could have long-term benefits for maternal and child health, resulting in improved survival and child development.

关于静脉注射铁剂对马拉维怀孕三个月妇女贫血症影响的随机对照试验(REVAMP - TT)的方案和统计分析计划。
背景:贫血影响着全球 40% 的孕妇,导致产妇死亡、早产、出生体重不足和婴儿发育不良。在非洲,超过 40% 的贫血病例是由缺铁引起的。对于中低收入国家(LMIC)来说,口服铁补充剂不足以达到目前世界卫生组织的目标。我们假设,在贫血恢复方面,单次静脉注射羧甲基铁(FCM)可能比口服铁剂更有效,尤其是在妇女接受产前检查较晚的情况下:这是一项由比尔及梅琳达-盖茨基金会资助的双臂平行开放标签个体随机对照试验,针对疟疾快速诊断检测阴性的中度或重度贫血孕妇--毛细血管血红蛋白 REVAMP 试验(试验注册号 ACTRN12618001268235,盖茨赠款号 INV-010612)。在 REVAMP-TT 试验中,招募和治疗均在初级保健中心进行。该试验将在马拉维松巴地区招募 590 名妇女。主要结果是贫血妇女的比例--静脉血红蛋白讨论:这项研究将确定在初级保健中心提供的 FCM 是否能有效、安全、可行地治疗马拉维怀孕三个月妇女的中度至重度贫血。这项干预措施可为孕产妇和儿童健康带来长期益处,从而提高存活率并促进儿童发育。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gates Open Research
Gates Open Research Immunology and Microbiology-Immunology and Microbiology (miscellaneous)
CiteScore
3.60
自引率
0.00%
发文量
90
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信